当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > HTLV-1-like particles and HTLV-1-related DNA sequences in an unambiguous case of Sèzary syndrome.

HTLV-1-like particles and HTLV-1-related DNA sequences in an unambiguous case of Sèzary syndrome.

Abstract：

:An unambiguous case of Sèzary syndrome associated with the presence of unusual retroviral infection markers is described. The blood smear showed 15% typical Sèzary cells but also rare atypical lymphocytes with convoluted nuclei, evocative of characteristic adult T-cell leukemia (ATL) flower cells. However, the patient did not present any clinical or biological manifestations of ATL, and human T-cell leukemia virus type 1 (HTLV-1) serology was consistently negative. After being cultured for 4 months, peripheral blood mononuclear cells (PBMC) produced typical type C retrovirus-like particles with budding forms strongly resembling HTLV-1 virions. The producer cells did not express HTLV-1-specific antigens detectable by indirect immunofluorescence (IIF). Southern blotting of uncultured PBMC DNA, submitted to digestion with the restriction enzymes PstI and SacI, and hybridized with a full genomic HTLV-1 probe, showed the presence of specific homologous sequences, absent in all of the healthy donor control PBMC DNAs. These HTLV-1-like sequences presented a restriction enzyme pattern distinct from that of the HTLV-1 prototype genome and of other HTLV-1 proviruses studied up to now. Polymerase chain reaction (PCR) with highly conserved HTLV-1 derived pol and env primers was consistently negative with the patient's DNA. All these results taken together suggest that our patient carries a retroviral agent partially homologous to, but probably different from HTLV-1. The possibility is discussed that this type of retroviral agent might be associated with a subtype of cutaneous T-cell lymphoma (CTCL) represented by a typical Sèzary syndrome with a very low percentage of ATL-like flower cells in the blood smear.

journal_name

Leukemia

journal_title

Leukemia

authors

Bazarbachi A,Saal F,Laroche L,Lasneret J,Gessain A,Daniel MT,Périès J

subject

Has Abstract

pub_date

1994-01-01 00:00:00

pages

201-7

issue

1

eissn

0887-6924

issn

1476-5551

journal_volume

8

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation.

    abstract：:A relationship was proved between constitutive activity of leukemic cell c-jun-N-terminal kinase (JNK) and treatment failure in AML. Specifically, early treatment failure was predicted by the presence of constitutive JNK activity. The mechanistic origins of this association was sought. A multidrug resistant leukemic c...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402457

    authors： Cripe LD,Gelfanov VM,Smith EA,Spigel DR,Phillips CA,Gabig TG,Jung SH,Fyffe J,Hartman AD,Kneebone P,Mercola D,Burgess GS,Boswell HS

    更新日期：2002-05-01 00:00:00

  • Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

    abstract：:JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and int...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0638-y

    authors： Austin RJ,Straube J,Bruedigam C,Pali G,Jacquelin S,Vu T,Green J,Gräsel J,Lansink L,Cooper L,Lee SJ,Chen NT,Lee CW,Haque A,Heidel FH,D'Andrea R,Hill GR,Mullally A,Milsom MD,Bywater M,Lane SW

    更新日期：2020-04-01 00:00:00

  • Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas.

    abstract：:Germline CD95 (also known as FAS, APT1 and APO1) gene mutations have been associated with benign lymphoproliferative diseases and autoimmune processes. Somatic mutations have been reported in human tumours, including lymphomas. Since marginal zone B cell lymphomas usually arise in a background of chronic inflammation,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401708

    authors： Bertoni F,Conconi A,Luminari S,Realini C,Roggero E,Baldini L,Carobbio S,Cavalli F,Neri A,Zucca E

    更新日期：2000-03-01 00:00:00

  • New structural chromosomal rearrangements in congenital leukemia.

    abstract：:The karyotypic abnormalities and clinical data on three patients in whom acute leukemia was diagnosed within the first 6 months of life are presented. The four structural chromosomal rearrangements detected in the bone marrow from these patients, i.e., t(7;12)(q36;p13) and t(1;19)(q11;q11) in case 1, t(2;10;11;12)(q21...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Heim S,Békàssy AN,Garwicz S,Heldrup J,Wiebe T,Kristoffersson U,Mandahl N,Mitelman F

    更新日期：1987-01-01 00:00:00

  • Sensitive and reproducible detection of occult disease in patients with follicular lymphoma by PCR amplification of t(14;18) both pre- and post-treatment.

    abstract：:The t(14;18) chromosomal translocation occurs in most follicular non-Hodgkin's lymphomas and places the Bcl-2 gene on chromosome 18q21 into the immunoglobulin JH region on chromosome 14q32. This translocation can be exploited to detect clonal malignant cells bearing this genetic alteration. A polymerase chain reaction...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Berinstein NL,Jamal HH,Kuzniar B,Klock RJ,Reis MD

    更新日期：1993-01-01 00:00:00

  • Cytogenetics and oncogenes.

    abstract：:There is abundant evidence that leukemia arise through somatically acquired genetic changes. Familial or congenital predisposition is rarely involved. These genetic changes are often visible as chromosomal aberrations. Molecular analyses of the DNA sequences rearranged in leukemia has demonstrated the presence of cell...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Hagemeijer A

    更新日期：1992-11-01 00:00:00

  • The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells.

    abstract：:A monoclonal antibody (17F11) was raised by immunization of a Balb/c mouse with leukemic blasts from a patient with acute non-lymphocytic leukemia (ANLL). This antibody recognizes most leukemic blasts of myeloid but not of lymphoid lineage and no peripheral blood cells. By screening NIH-3T3 fibroblasts transfected wit...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Bühring HJ,Ullrich A,Schaudt K,Müller CA,Busch FW

    更新日期：1991-10-01 00:00:00

  • A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside.

    abstract：:The purpose of this paper was to ascertain whether results obtained in cell cultures of AML clonogenic blast cells would provide a useful model for a clinical regimen that combines fludarabine (F-ara-AMP) and cytosine arabinoside (ara-C). In the cultures the nucleoside F-ara-A was used. Blast cells from the continuous...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Rayappa C,McCulloch EA

    更新日期：1993-07-01 00:00:00

  • EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.

    abstract：:The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody panels in order to achieve maximally comparable results among...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2012.122

    authors： Kalina T,Flores-Montero J,van der Velden VH,Martin-Ayuso M,Böttcher S,Ritgen M,Almeida J,Lhermitte L,Asnafi V,Mendonça A,de Tute R,Cullen M,Sedek L,Vidriales MB,Pérez JJ,te Marvelde JG,Mejstrikova E,Hrusak O,Szczepańs

    更新日期：2012-09-01 00:00:00

  • Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.

    abstract：:It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is often implicated i...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2011.46

    authors： Martelli AM,Evangelisti C,Chappell W,Abrams SL,Bäsecke J,Stivala F,Donia M,Fagone P,Nicoletti F,Libra M,Ruvolo V,Ruvolo P,Kempf CR,Steelman LS,McCubrey JA

    更新日期：2011-07-01 00:00:00

  • bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient.

    abstract：:Using the polymerase chain reaction and Southern blot analysis the expression was detected of a bcr-abl mRNA lacking abl exon a2. This was due to a corresponding unusual localization of the breakpoint in the c-abl gene and was seen in a patient with Philadelphia (Ph) chromosome positive chronic myelogeneous leukemia i...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： van der Plas DC,Soekarman D,van Gent AM,Grosveld G,Hagemeijer A

    更新日期：1991-06-01 00:00:00

  • C-Jun modulates apoptosis but not terminal cell differentiation in murine erythroleukemia cells.

    abstract：:The proto-oncogene c-Jun has been implicated in the control of cell proliferation and differentiation and more recently in the regulation of apoptosis. We have previously reported the involvement of c-Jun in the erythroid differentiation block in murine erythroleukemia (MEL) cells. As reported here, we investigated th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402350

    authors： Poindessous-Jazat V,Augery-Bourget Y,Robert-Lézénès J

    更新日期：2002-02-01 00:00:00

  • B cells from bovine leukemia virus- (BLV) infected sheep with hematological disorders express the CD5 T cell marker.

    abstract：:Though peripheral blood B cells from healthy sheep were known to be devoid of the CD5 T cell marker, it appears from our study that most B cells from bovine leukemia virus- (BLV) infected sheep with hematological disorders express both the CD5 marker and surface IgM. The possible meaning of this T cell marker expressi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Letesson JJ,Mager A,Mammerickx M,Burny A,Depelchin A

    更新日期：1990-05-01 00:00:00

  • Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.

    abstract：:The prognostic value of IL7-receptor pathway (IL7Rp) mutations in T-cell acute lymphoblastic leukemia (T-ALL) remains unclear. We performed a comprehensive study of 200 adult patients with T-ALL included in the GRAALL2003/2005 protocols to address the clinical significance of IL7Rp mutations. Next-generation sequencin...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/s41375-019-0685-4

    authors： Kim R,Boissel N,Touzart A,Leguay T,Thonier F,Thomas X,Raffoux E,Huguet F,Villarese P,Fourrage C,Passini L,Hunault M,Lepretre S,Chevallier P,Braun T,Lhéritier V,Chantepie S,Maury S,Escoffre M,Tavernier E,Chalandon

    更新日期：2020-07-01 00:00:00

  • Establishment of multipotential and antigen presenting cell lines derived from myeloid leukemias in GM-CSF transgenic mice.

    abstract：:In this study neonatal mice expressing a GM-CSF transgene (GMT mice), and their normal littermate controls, were infected with Moloney murine leukemia virus (MoMLV) to examine in vivo tumorigenesis. By 200 days, all of the GMT mice had died whereas median survival had not been reached in the littermates (P < 0.0003). ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400614

    authors： Rasko JE,Metcalf D,Alexander B,Strasser A,Begley CG

    更新日期：1997-05-01 00:00:00

  • Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.

    abstract：:Chromosomal translocations involving the MYC oncogene are a hallmark of Burkitt lymphoma but they are only found in a varying frequency in mature Burkitt-type acute lymphoblastic leukemia (B-ALL). We have investigated samples of 56 sporadic Burkitt leukemia/lymphoma patients for the translocations t(8;14)(q24;q32), t(...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403847

    authors： Burmeister T,Schwartz S,Horst HA,Rieder H,Gökbuget N,Hoelzer D,Thiel E

    更新日期：2005-08-01 00:00:00

  • BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Ev

    abstract：:The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402150

    authors： Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

    更新日期：2001-08-01 00:00:00

  • Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction.

    abstract：:We used a modification of the polymerase chain reaction (PCR) to amplify the specific bcr-abl mRNA from 14 patients with chronic myeloid leukemia (CML) who had previously received non T cell depleted allogenic bone marrow transplantation (BMT). Two types of reactions were used: a single step amplification with 5' and ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Delfau MH,Kerckaert JP,Collyn d'Hooghe M,Fenaux P,Laï JL,Jouet JP,Grandchamp B

    更新日期：1990-01-01 00:00:00

  • Resistance to RadLV-induced leukemia: non-participation of splenic natural killer cells.

    abstract：:The phenotypic expression of genetically determined resistance to radiation leukemia virus (RadLV)-induced leukemia in mice has been shown to reside in the bone marrow. Because the bone marrow contains precursors of natural killer (NK) cells, known to play a role in retrovirally induced infections, and because these c...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： St-Pierre Y,Hugo P,Lemieux S,Lussier G,Potworowski EF

    更新日期：1988-08-01 00:00:00

  • Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

    abstract：:We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324 patients with newly diagnosed AML were enrolled in 5 prospective treatment trials of the German-Austrian AML Study Group. After fi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.23

    authors： Wattad M,Weber D,Döhner K,Krauter J,Gaidzik VI,Paschka P,Heuser M,Thol F,Kindler T,Lübbert M,Salih HR,Kündgen A,Horst HA,Brossart P,Götze K,Nachbaur D,Köhne CH,Ringhoffer M,Wulf G,Held G,Salwender H,Benner A,G

    更新日期：2017-06-01 00:00:00

  • De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.

    abstract：:Dysplastic hematopoiesis is the morphological hallmark of myelodysplastic syndromes. Dysplastic features in one or more lineages are also found frequently in bone marrow aspirates from patients with de novo AML and have been associated with an unfavorable prognosis. We asked whether dyshematopoiesis is an independent ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Gahn B,Haase D,Unterhalt M,Drescher M,Schoch C,Fonatsch C,Terstappen LW,Hiddemann W,Büchner T,Bennett JM,Wörmann B

    更新日期：1996-06-01 00:00:00

  • Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.

    abstract：:Protein kinase CK2 sustains acute myeloid leukemia cell growth, but its role in leukemia stem cells is largely unknown. Here, we discovered that the CK2 catalytic α and regulatory β subunits are consistently expressed in leukemia stem cells isolated from acute myeloid leukemia patients and cell lines. CK2 inactivation...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.209

    authors： Quotti Tubi L,Canovas Nunes S,Brancalion A,Doriguzzi Breatta E,Manni S,Mandato E,Zaffino F,Macaccaro P,Carrino M,Gianesin K,Trentin L,Binotto G,Zambello R,Semenzato G,Gurrieri C,Piazza F

    更新日期：2017-02-01 00:00:00

  • The role of TGFβ in hematopoiesis and myeloid disorders.

    abstract：:The role of transforming growth factor-β (TGFβ) signaling in embryological development and tissue homeostasis has been thoroughly characterized. Its canonical downstream cascade is well known, even though its true complexity and other non-canonical pathways are still being explored. TGFβ signaling has been described a...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-019-0420-1

    authors： Bataller A,Montalban-Bravo G,Soltysiak KA,Garcia-Manero G

    更新日期：2019-05-01 00:00:00

  • Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

    abstract：:The outcome of a cohort of 218 consecutive patients who failed to respond to a single course of standard daunorubicin plus ARAC (three + seven) induction regimen has been retrospectively evaluated to assess the characteristics of this group of AML patients and the effectiveness of second-line induction programs. Seven...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Liso V,Iacopino P,Avvisati G,Petti MC,Broccia G,Carotenuto M,Falda M,Fazi P,Lazzarino M,Leoni P,Mirto S,Pucci G,Nobile F,Nosari AM,Specchia G,Stasi R,Tabilio A,Mandelli F

    更新日期：1996-09-01 00:00:00

  • CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.

    abstract：:Upregulation of the immunosuppressive cell surface glycoprotein, CD200, is a common feature of acute myeloid leukemia (AML) and is associated with poor patient outcome. We investigated whether CD200 overexpression on AML cells could specifically compromise patient natural killer (NK) cell anti-tumor responses. We foun...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.1

    authors： Coles SJ,Wang EC,Man S,Hills RK,Burnett AK,Tonks A,Darley RL

    更新日期：2011-05-01 00:00:00

  • Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia.

    abstract：:Patients with chronic lymphocytic leukemia (CLL) have defects in both cellular and humoral immunity. Since CD152 (CTLA-4) plays a critical role in downregulating T-cell responses, we studied the expression of surface and cytoplasmic CD152 (sCD152 and cCD152, respectively) in freshly isolated T cells from treatment-naï...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403907

    authors： Motta M,Rassenti L,Shelvin BJ,Lerner S,Kipps TJ,Keating MJ,Wierda WG

    更新日期：2005-10-01 00:00:00

  • AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.

    abstract：:The requirement that leukemic Gata1 mutations be present in cells harboring trisomy 21 led to the discovery that overexpression of ERG drives aberrant megakaryopoiesis. Given that constitutive PI3K/AKT signaling is a frequent component of hematologic malignancies and the relationship between AKT and Notch in this line...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.33

    authors： Stankiewicz MJ,Crispino JD

    更新日期：2013-06-01 00:00:00

  • Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.

    abstract：:Galectins constitute a family of lectins that specifically exhibit the affinity for beta-galactosides and modulate various biological events. Galectin-9 is a tandem-repeat type galectin with two carbohydrate recognition domains and has recently been shown to have an anti-proliferative effect on cancer cells. We invest...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.25

    authors： Kobayashi T,Kuroda J,Ashihara E,Oomizu S,Terui Y,Taniyama A,Adachi S,Takagi T,Yamamoto M,Sasaki N,Horiike S,Hatake K,Yamauchi A,Hirashima M,Taniwaki M

    更新日期：2010-04-01 00:00:00

  • A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

    abstract：:The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.225

    authors： Burnett AK,Russell NH,Hills RK,Kell J,Nielsen OJ,Dennis M,Cahalin P,Pocock C,Ali S,Burns S,Freeman S,Milligan D,Clark RE

    更新日期：2017-02-01 00:00:00

  • BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

    abstract：:Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against chronic lymphocytic leukemia (CLL) in early clinical trials. Understanding the molecular ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.358

    authors： Cheng S,Ma J,Guo A,Lu P,Leonard JP,Coleman M,Liu M,Buggy JJ,Furman RR,Wang YL

    更新日期：2014-03-01 00:00:00